Eli Lilly Ceo Talks Deal

Media Summary: "We're starting this because we believe it could work," The increasing popularity of GLP-1 weight-loss drugs has driven drugmaker

Eli Lilly Ceo Talks Deal - Detailed Analysis & Overview

"We're starting this because we believe it could work," The increasing popularity of GLP-1 weight-loss drugs has driven drugmaker

Photo Gallery

Eli Lilly CEO talks deal to cut medication prices with the Trump administration

Eli Lilly CEO David Ricks on $1T market value, obesity pill launch and drug pipeline outlook

Eli Lilly CEO: Seeing global demand for weight loss drug Mounjaro

Eli Lilly CEO: Our pill supply can 'reach the planet'

Eli Lilly CEO explains White House medication cost deal

AI and GLP-1 drugs: Eli Lilly & Co.'s CEO talks of focus beyond 150 years

Eli Lilly CEO David Ricks on Q2 earnings, obesity pill late-stage trial results

Eli Lilly CFO Lucas Montarce Talks Weight Loss Pill, Business Outlook | Bloomberg Talks

Eli Lilly CEO on slashing insulin prices, approval timelines for weight-loss and Alzheimer's drugs

Gerry Dick talks one-on-one with Eli Lilly CEO Dave Ricks

Eli Lilly CEO talks partnering with AbCellera Biologics to co-develop a coronavirus cure

Eli Lilly CEO Dave Ricks on revolutionizing healthcare and medicine

View Detailed Profile

Eli Lilly CEO talks deal to cut medication prices with the Trump administration

Eli Lilly CEO talks deal to cut medication prices with the Trump administration

NBC News' Tom Llamas

Eli Lilly CEO David Ricks on $1T market value, obesity pill launch and drug pipeline outlook

Eli Lilly CEO David Ricks on $1T market value, obesity pill launch and drug pipeline outlook

Eli Lilly

Eli Lilly CEO: Seeing global demand for weight loss drug Mounjaro

Eli Lilly CEO: Seeing global demand for weight loss drug Mounjaro

Eli Lilly

Eli Lilly CEO: Our pill supply can 'reach the planet'

Eli Lilly CEO: Our pill supply can 'reach the planet'

Eli Lilly

Eli Lilly CEO explains White House medication cost deal

Eli Lilly CEO explains White House medication cost deal

Eli Lilly CEO

AI and GLP-1 drugs: Eli Lilly & Co.'s CEO talks of focus beyond 150 years

AI and GLP-1 drugs: Eli Lilly & Co.'s CEO talks of focus beyond 150 years

Eli Lilly

Eli Lilly CEO David Ricks on Q2 earnings, obesity pill late-stage trial results

Eli Lilly CEO David Ricks on Q2 earnings, obesity pill late-stage trial results

CNBC's Angelica Peebles and

Eli Lilly CFO Lucas Montarce Talks Weight Loss Pill, Business Outlook | Bloomberg Talks

Eli Lilly CFO Lucas Montarce Talks Weight Loss Pill, Business Outlook | Bloomberg Talks

Eli Lilly

Eli Lilly CEO on slashing insulin prices, approval timelines for weight-loss and Alzheimer's drugs

Eli Lilly CEO on slashing insulin prices, approval timelines for weight-loss and Alzheimer's drugs

CNBC's Meg Tirrell and David Ricks,

Gerry Dick talks one-on-one with Eli Lilly CEO Dave Ricks

Gerry Dick talks one-on-one with Eli Lilly CEO Dave Ricks

In November,

Eli Lilly CEO talks partnering with AbCellera Biologics to co-develop a coronavirus cure

Eli Lilly CEO talks partnering with AbCellera Biologics to co-develop a coronavirus cure

"We're starting this because we believe it could work,"

Eli Lilly CEO Dave Ricks on revolutionizing healthcare and medicine

Eli Lilly CEO Dave Ricks on revolutionizing healthcare and medicine

The increasing popularity of GLP-1 weight-loss drugs has driven drugmaker

Eli Lilly CEO David Ricks breaks down Q1 earnings, obesity drug trial results

Eli Lilly CEO David Ricks breaks down Q1 earnings, obesity drug trial results

Eli Lilly CEO